Skip to main content
Navigate Up
Sign In

University of Colorado Denver


Mechanisms and Barriers in Nanomedicine

Future Dates TBA

There is a growing sentiment in the field that in order to increase the availability of nanodrugs for patients, the biological, pathophysiological, immunological and manufacturing/regulatory barriers to effective translation need to be addressed.

The goals of the two-day Mechanisms and Barriers in Nanomedicine workshop are to: 

  • provide an educational forum on the barriers to nanoparticle translation; 
  • provide a paradigm shift to overcome these problems; and
  • allow for open discussion among faculty, postdocs and graduate students, to trigger new ideas and concepts.

The workshop will consist of informal, non-concurrent sessions, followed by discussion. Talks will focus on mechanisms, problems, and solutions of the following aspects of nanomedicine:

  • bio-nano interface, immune recognition, and toxicity
  • complement
  • ​in vitro and in vivo barriers
  • no-engineering and design
  • ​metastatic cells, stem cells, and relevance of mouse models
  • regulatory/industrial hurdles

Discussions will focus on questions suggested by the audience.

Submit an Abstract, Topic, or Question

Students, faculty, and postdocs are invited to submit abstracts for posters on mechanistic studies focused on problems in nanomedicine. Of those, one poster abstract will be selected for a brief oral presentation. The remaining abstracts will be presented as posters, with the best poster receiving a prize. The deadline has been extended for post-docs and graduate students through June 30, 2016. To submit and abstract, email​.

Attendees are also welcome to submit a provocative topic/question for the discussion session to the organizers via email​.

An informal atmosphere, wine, and food are guaranteed. To register, please click on the "Registration" tab below. See you in beautiful Colorado!

Past sessions and speakers are listed below. 

Morning session 1: Immunological barriers, macrophages and toxicity

Nanosafety: No small issue​​ Moien Moghimi​
Macrophage reprogramming with nanoparticles​ Diana Boraschi​
Complement and immune uptake of nanomedicines: Lessons from iron oxide nanworms​ Dmitri Simberg​

Morning session 2: Tumor barriers and targets

Keynote: Tumor-penetrating peptides in nanoparticle targeting​ Erkki Ruoslahti​
Where the wild things are: Perivascular regulation of tumor cell dormancy and drug resistance​ Cyrus Ghajar​
​Immunotherapy targeting tumor microenvironment and opportunities for nanomedicine Stephen Dow​

Afternoon session 1: Targeting tumor microenvironment

Improving nano-drugs' therapeutic efficacy through their interaction with tumor microenvironment​ Chezy Barenholz​
Nanobioconjugates delivered through multiple biobarriers regulate laminin-411 - Notch pathways​ Julia Ljubimova​
Exploting cells in the tumor microenvironment for nanovector based therapy​ Biana Godin​

Afternoon session 2: Formulation barriers

The 4S parameters in the rational design of nanomedicines​ Paolo Decuzzi​
Overcoming barriers for nanoparticle delivery using circulatory cells​ ​Samir Mitragotri
Biologics and peptides by a novel encapsulation process​ Robert Prud'homme​

Morning session 1: Clinical aspects of nanomedicine

Optimizing nanoparticle delivery of chemotherapeutics - The clinical challenge​ Alberto Gabizon​
Impact of nanoparticles on the tumor immunologic millieu: Promise and peril​ Irene La-Beck​
Nanoparticle-based MRI on tumor associated macrophages: Preclinical and clinical utility​ Natalie Serkova​

Morning session 2: Manufacturing and regulatory/funding hurdles

Challenges and opportunities in Nano-commercialization​ Shadi Farhangrazi​
Translation of a cancer nanotherapeutic into the clinic: A view from the trenches​ Len Pagliaro​
Preclinical immunotoxicity studies of nanotechnolog​y-formulated drugs​ Marina Dobrovolskaia​
Perspective on nanomedicine climate and the science advances​ Dorothy Farrell

Afternoon session 1: Organ/tissue/cell-specific barriers

Biophysical barriers in respiratory drug delivery​ Hugh Smyth​
To target or not to target: Lessons from RNAi-based targeted lipid-based nanoparticles​ Dan Peer​
Physical and chemical mechanisms of targeting selectivity for mRNA nanomedicines for tumor immunotherapy​ Heinrich Haas​

Afternoon session 2: Innovative approaches and formulations

Hyperthermia approaches for enhanced delivery of polymer therapeutics​ Hamid Ghandehari​
Extracellular vesicles-mediated penetration of therapeutic compounds in solid tumors​ Ji Ho (Joe) Park​
Nanoparticle-prodrug combination approach for treating neuroblastoma ​ Michael Chorny​
Nanoghosts as a natural nonviral gene delivery platform for targeting cancers​ Marcelle Machlouf​


Thomas Anchordoquy, University of Colorado, US
Chezy Barenholz, The Hebrew University of Jerusalem, Israel
Diana Boraschi, National Research Council, Italy
Michael Chorny, Children's Hospital of Philadelphia, US
Paolo Decuzzi, Italian Institute of Technology in Genoa, Italy
Marina Dobrovolskaia, Nanotechnology Characterization Laboratory, US
Stephen Dow, Colorado State University, US
​Shadi Farhangrazi, Biotrends International and University of Denver​, US
Dorothy Farrell, National Cancer Institute​, US
Alberto Gabizon, The Hebrew University of Jerusalem​, Israel
Cyrus Ghajar, Fred Hutchinson Cancer Research Center, US
Hamid Ghandehari, University of Utah, US
Heinrich Haas, BioNTech RNA Pharmaceuticals GmbH, Germany
Irene La-Beck, Texas Tech University, US
Julia Ljubimova, Cedars-Sinai Hospital, US
Gabriel Lopez-Berestein, MD Anderson Cancer Center, US
Marcelle Machlouf, Tel Aviv University, Israel
Samir Mitragotri, University of California, Santa Barbara, US
Moien Moghimi, Durham University, UK
Len Pagliaro, Siva Therapeutics, US
Ji Ho Park, Kaist, South Korea
Dan Peer, Tel Aviv University, Israel​
Robert Prud'homme, Princeton University, US
Erkki Ruoslahti, Prebys-Sanford-Burnham, US
Natalie Serkova, University of Colorado, US
Dmitri Simberg, University of Colorado, US
Hugh Smyth, University of Texas at Austin, US
Biana Godin Vilentchouk, Methodist Hospital​​​​​​, US


Event Sponsors

CU School of Pharmacy     CU Cancer Center     Quidel     

The AAPS Rocky Mountain regional discussion group (RMDG) is also a sponsor.